The Department of Urology of the New York Hospital
(Given January 31, 1941)
Carcinoma of the Prostate Gland
Carcinoma of the prostate, because of its frequency and its essentially fatal nature, presents the urologist with his most baffling problem. Young’s statistics (1935) reveal that a fifth of the male patients who seek relief of obstruction of the vesical neck have carcinoma of the prostate.
Pathology. A striking morphologic peculiarity of carcinoma of the prostate gland, that has been emphasized by most authors, is the diversity of its forms. In the same case, in different portions, the carcino-matous proliferation may be found at one time as an adenocarcinoma and again as a scirrhous, a medullary, or a squamous-cell carcinoma.
A large percentage of prostatic carcinomas are associated with benign hypertrophy. In only 10 (13 per cent) of the 72 cases studied by Wilson and McGrath was there no evidence of associated hypertrophy.
Chart I
Incidence, By Age-Groups, of Carcinoma in Relation to Benign Enlargement in 280 Cases
|
Age of group |
Prostates examined |
Per cent showing carcinoma |
Per cent showing benign enlargement |
Per cent of carcinomas which arose in a prostate with benign enlargement |
Per cent of benign enlargement which also showed carcinoma |
|
31-40
|
28
|
0%
|
4% ( 1)
|
0%
|
0%
|
|
41-50
|
23
|
17% ( 4)
|
30% ( 7)
|
25%
|
14%
|
|
51-60
|
65
|
14% ( 9)
|
37% (24)
|
50%
|
21%
|
|
61-70
|
77
|
23% (18)
|
67% (52)
|
66%
|
23%
|
|
71-80
|
63
|
21% (13)
|
68% (43)
|
46%
|
14%
|
|
81-90
|
24
|
29% ( 7)
|
75% (18)
|
71%
|
27%
|
In his very complete study of 280 prostates from men between the ages of 31 and 90 years, Robert A. Moore found the occurrence of carcinoma and benign enlargement to be as shown in Chart I. It is evident, therefore, that the possibility of carcinoma must be kept in mind in every case of prostatic hypertrophy.
Numerous careful studies show that in over 75 per cent of cases the carcinoma starts in the posterior lobe (the portion of the gland which does not participate in benign adenomatous hypertrophy).
Prostatic carcinoma is, as a rule, insidious and slow-growing, though highly malignant, and may remain confined to the prostate and periprostatic region for long periods. Only 10 to 20 per cent, according to Barringer, are radiosensitive.
In many cases, by the time the growth has become sufficiently advanced to be clinically diagnosed, it has extended beyond the posterior lobe into the lateral and median lobes and upward to the base of the prostate. There it may penetrate the capsule and involve the seminal vesicles. Through the prostate’s rich supply of lymphatics, the carcinoma may extend to the pelvic nodes, or, by the perirectal plexus, to the abdominal nodes. Dissemination through the blood stream may occur early, and distant metastases, particularly in the bones, are often detected before the occurrence of local symptoms. The small prostatic tumor often disseminates widely. The high frequency of skeletal metastases, and the predilection for the pelvis and lumbar vertebrae, have been noted by practically all observers.
Symptoms. The symptoms are not characteristic. Disturbances of urination are usually the first symptoms, but advanced carcinoma may be present without urinary symptoms. Pain — referred to the sacroiliac region, rectum, perineum, or suprapubic area — is often an early symptom, and may be due to metastases to the bones. Terminal hematuria, retention, loss of weight and strength, and constipation are significant, but late, symptoms.
Diagnosis. Carcinoma of the prostate has, unfortunately, usually existed for a long period by the time it is recognized. The diagnosis is based upon the findings of rectal palpation and microscopic examination of a biopsy specimen removed by means of an instrument, such as the Lowsley biopsy instrument. In well-advanced cases recognition is usually not difficult; but in early cases, in the soft (medullary) type of carcinoma, and in carcinoma superimposed upon a benign hypertrophy, diagnosis may be difficult. A single, small nodule may easily escape notice, especially when masked by edematous prostatic tissue or in the absence of symptoms. The entire gland may be irregularly enlarged, of a board-like hardness, and fixed; but usually the growth is in the form of a nodule or hardened area in the posterior lobe, where it is readily palpable by rectum. Evidence of the fixed gland may be seen on cystourethroscopic examination.
Prognosis and Treatment. The prognosis in the past has been cheerless in the extreme. Over 95 per cent of the cases are beyond cure when first seen. The high early incidence of pelvic lymphadenopathy, capsular infiltration and invasion of the contiguous structures, and skeletal metastases precludes the successful surgical treatment of the disease in most cases.
In cases in which the carcinoma is confined to the prostate and periprostatic region, total or subtotal perineal prostatectomy yields a fair percentage of cures estimated upon a 3 to 5 years’ basis, and prolongations of life for considerably longer periods are not uncommon. If seen too late for hope of radical removal, partial perineal prostatectomy, or transurethral resection of the obstruction, with implantation of radon seeds, is the method of choice.
Improvement in prognosis is dependent on an increase in the number of early diagnoses, with radical removal.